Last updated: July 28, 2026
STIMATE (needs no refrigeration): market dynamics and financial trajectory, FDA status, exclusivity window, and generic/biosimilar risk
STIMATE (desmopressin acetate injection; needs no refrigeration) has a limited addressed patient base tied to nephrogenic diabetes insipidus (NDI) and nocturnal enuresis indications. Revenue trajectory is driven by (1) payer shift to lowest-net-cost injectable desmopressin options, (2) channel inventory cycles typical of single-source injectables, and (3) competitive pressure from alternative desmopressin delivery formats (intranasal, oral, and other injectable supply). Generic entry risk is concentrated in the “injectable desmopressin acetate” space and any Paragraph IV challenges to STIMATE-specific Orange Book listings, while market access depends on wholesaler availability and contracting.
No reliable, complete dataset is available in the provided context to quantify STIMATE’s actual revenue by year, segment, market share, net price, or realized reimbursement rates, or to map its exact Orange Book patent set, expiration dates, and litigation history.
As a result, a complete financial trajectory and market-size quantification cannot be produced from the available information.
What does STIMATE treat and how does that shape demand?
STIMATE is a desmopressin acetate injectable. Demand is concentrated in patient populations where clinicians prefer a ready-to-use injection that does not require cold-chain handling. That “no refrigeration” attribute affects procurement and logistics more than it changes clinical positioning in most formularies.
Key demand drivers
- Site-of-care: hospital outpatient, infusion centers, and office-administered injectable workflows where avoiding cold-chain reduces handling burden.
- Switchability: where payers and pharmacy & therapeutics committees treat “desmopressin injection” as interchangeable with other routes, except where clinical protocols specify injection.
- Supply reliability: for injectables, wholesaler supply stability can move prescriptions and reimbursement outcomes even without patent challenges.
How do payers typically position “no refrigeration” injectables in contracting?
Commercialization is usually influenced less by the thermal attribute itself and more by contracting mechanics:
- Net price pressure: competitive tendering and rebates can erode gross-to-net margins.
- Formulary placement: desmopressin products often face tiering against competing routes unless a plan has a dedicated injectable need.
- White-bag/administration carve-outs: provider billing models can change whether “no refrigeration” reduces admin cost enough to influence adoption.
Because no contract level terms, formulary data, or realized net price history is present here, the magnitude of margin impact cannot be quantified.
What patents protect STIMATE (desmopressin acetate injection needs no refrigeration)?
A defensible patent estate assessment requires the specific STIMATE Orange Book listing set (application numbers, patent numbers, and listed exclusivities) and any relevant litigation records. No such listing data is provided in the prompt context.
Which “patent estate” components matter for market exclusivity?
For an injectable desmopressin product, the exclusivity and patent shield typically hinges on:
- Active ingredient and composition-of-matter (if any are still listed specifically for STIMATE’s application).
- Formulation/vehicle patents (common in injectables).
- Method-of-use patents (less common for older desmopressin indications but possible depending on labeling strategy).
- Manufacturing process patents (sterility, fill-finish, or stabilization-related methods).
- Orange Book exclusivity (application-specific periods tied to 505(b)(2) or 505(j) frameworks).
How strong is the patent estate for STIMATE?
Strength depends on:
- number of unexpired, relevant Orange Book patents at the time of generic launch
- whether any patents were successfully challenged and settled via licensing or court entry dates
- whether exclusivity is layered (patents plus exclusivity)
No Orange Book identifiers or patent numbers are provided; therefore, patent strength cannot be scored.
When does STIMATE lose exclusivity and what is the generic entry timeline?
An accurate exclusivity timeline requires:
- Orange Book patent expiration dates for STIMATE
- any periods of pediatric exclusivity, orphan drug exclusivity, or 180-day exclusivity triggers
- FDA approval history and application type
The required dates and triggers are not present in the provided context.
What generic entry risks exist for STIMATE?
Generic entry risk would typically show up via:
- ANDA Paragraph IV filings to challenge listed patents
- Section viii statement/notice timing affecting settlement and “first-to-file” exclusivity
- Patent settlement timelines that can delay or permit launch
No Paragraph IV notices, settlement agreements, or first-filer status is provided here.
What is the Orange Book status of STIMATE?
Orange Book status requires the exact FDA application number(s) and listing details. None are supplied in the prompt context.
Which entries should be checked for STIMATE?
For each STIMATE listing, analysts typically verify:
- Active ingredient scope: desmopressin acetate strength and dosage form
- Dosage form: injection (and whether it is preservative-free, buffered, etc.)
- Listed patents: formulation, method of use, and manufacturing
- Exclusivity codes: patent-term extension or exclusivity types tied to the approval pathway
No listing content is available here to report.
What patent litigation affects STIMATE and desmopressin injection?
A litigation timeline needs:
- case captions and courts
- complaint and answer dates
- motions (dismissal, preliminary injunction)
- settlement dates and terms
- any appellate outcomes
No litigation data is provided in the prompt context.
How does STIMATE compare with other desmopressin products on market access and adoption?
Even without exact STIMATE financials, the competitive landscape for desmopressin products generally falls into:
- Other desmopressin injection brands (if available)
- Intranasal desmopressin for enuresis
- Oral desmopressin (tablets) for enuresis and other indications depending on labeling
- Unbranded generics for older desmopressin molecules where patents have expired
Which differences typically matter to decision-makers?
- Thermal stability and cold-chain costs
- Dosing accuracy and administration workflow
- Facility protocols for handling controlled or specialty injectables
- Payer coverage rules by route
A quantitative comparison cannot be produced without market share and net price data.
What formulations are protected by STIMATE patents?
Formulation protection typically covers one or more of:
- buffered solution composition
- stabilizers and preservatives
- osmolarity and pH ranges
- concentration, unit-fill design, and container closure system
- sterilization and stabilization methods for maintaining potency
No STIMATE formulation patent numbers or claims are provided here, so the protected formulation scope cannot be enumerated.
What commercial metrics determine STIMATE’s financial trajectory?
STIMATE’s financial trajectory is usually determined by:
- Volume: prescriptions, vial demand, or patient-days treated
- Net price: gross-to-net effects from rebates and chargebacks
- Channel dynamics: wholesaler inventory turns and buy-in patterns
- Contracting: specialty pharmacy versus provider-administered reimbursement
- Supply continuity: production outages can create temporary market share gains for competitors and vice versa
- Exclusivity and generic entry: the single biggest step-change variable for injectables
No time-series financial or claims data is present here; a year-by-year forecast or realized revenue curve cannot be produced.
Key Takeaways
- STIMATE demand is tied to limited desmopressin injection patient populations and is sensitive to procurement logistics where “no refrigeration” reduces handling burden.
- Market access is driven by net-price contracting and supply continuity rather than thermal stability alone.
- A complete financial trajectory and patent/generic-risk assessment cannot be generated without STIMATE-specific Orange Book listings, exclusivity/patent expiration dates, and litigation/Paragraph IV records.
FAQs
1) Does “no refrigeration” materially change STIMATE formulary placement versus cold-chain injectables?
It can reduce facility handling costs, but formulary placement is typically net-price and route-access dependent.
2) What indications drive STIMATE volume most consistently?
Desmopressin injection use is generally concentrated in nephrogenic diabetes insipidus and related enuresis labeling, with prescribing influenced by guideline adoption and payer coverage.
3) What are the most likely mechanisms of generic competition for injectable desmopressin products?
ANDA Paragraph IV challenges to Orange Book-listed patents tied to formulation, method of use, or manufacturing, followed by launch with label-and-route matching.
4) How do patent settlements usually affect STIMATE-like injectable products?
Settlements can set agreed launch dates or impose licensing terms that delay entry despite earlier ANDA readiness.
5) What operational factors most affect injectable desmopressin revenue volatility?
Supply reliability, wholesaler inventory cycles, and contract-driven net price changes tend to dominate quarter-to-quarter fluctuations.
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (accessed via FDA Orange Book database).
- FDA Drug Shortages database (if applicable).
- FDA labeling for STIMATE (desmopressin acetate injection; no refrigeration).
-patent-expirations.png "STIMATE (NEEDS NO REFRIGERATION) drug patent expirations")
